Oncopeptides AB (publ) (ONCO.ST)
SEK 1.95
(-2.01%)
SEK 1.95
(-2.01%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -249.11 Million SEK | 26.29% |
| 2022 | -337.95 Million SEK | 76.37% |
| 2021 | -1.43 Billion SEK | 10.31% |
| 2020 | -1.59 Billion SEK | -115.29% |
| 2019 | -740.7 Million SEK | -76.59% |
| 2018 | -419.44 Million SEK | -69.39% |
| 2017 | -247.62 Million SEK | -116.36% |
| 2016 | -114.44 Million SEK | -114.56% |
| 2015 | -53.34 Million SEK | -61.18% |
| 2014 | -33.09 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -67.7 Million SEK | 16.63% |
| 2024 Q2 | -73.24 Million SEK | -8.18% |
| 2023 Q2 | -56.33 Million SEK | 20.69% |
| 2023 FY | -249.11 Million SEK | 26.29% |
| 2023 Q4 | -81.21 Million SEK | -100.31% |
| 2023 Q3 | -40.54 Million SEK | 28.03% |
| 2023 Q1 | -71.02 Million SEK | 22.03% |
| 2022 Q1 | -98.58 Million SEK | 74.98% |
| 2022 FY | -337.95 Million SEK | 76.37% |
| 2022 Q2 | -59.82 Million SEK | 39.32% |
| 2022 Q4 | -91.09 Million SEK | -3.01% |
| 2022 Q3 | -88.43 Million SEK | -47.82% |
| 2021 Q2 | -24.11 Million SEK | 89.72% |
| 2021 Q1 | -234.66 Million SEK | 54.25% |
| 2021 FY | -1.43 Billion SEK | 10.31% |
| 2021 Q3 | -777.54 Million SEK | -3124.2% |
| 2021 Q4 | -393.99 Million SEK | 49.33% |
| 2020 Q2 | -401.04 Million SEK | -34.88% |
| 2020 FY | -1.59 Billion SEK | -115.29% |
| 2020 Q4 | -512.96 Million SEK | -33.81% |
| 2020 Q1 | -297.32 Million SEK | -21.41% |
| 2020 Q3 | -383.35 Million SEK | 4.41% |
| 2019 Q4 | -244.9 Million SEK | -29.05% |
| 2019 Q3 | -189.78 Million SEK | -10.37% |
| 2019 Q2 | -171.94 Million SEK | -40.71% |
| 2019 Q1 | -122.19 Million SEK | -9.73% |
| 2019 FY | -740.7 Million SEK | -76.59% |
| 2018 FY | -419.44 Million SEK | -69.39% |
| 2018 Q4 | -111.36 Million SEK | -8.14% |
| 2018 Q3 | -102.98 Million SEK | 28.02% |
| 2018 Q1 | -62.03 Million SEK | 7.0% |
| 2018 Q2 | -143.07 Million SEK | -130.65% |
| 2017 Q3 | -51.57 Million SEK | 23.32% |
| 2017 FY | -247.62 Million SEK | -116.36% |
| 2017 Q4 | -66.7 Million SEK | -29.34% |
| 2017 Q2 | -67.26 Million SEK | -8.34% |
| 2017 Q1 | -62.08 Million SEK | -21.61% |
| 2016 Q4 | -51.05 Million SEK | -106.96% |
| 2016 FY | -114.44 Million SEK | -114.56% |
| 2016 Q3 | -24.66 Million SEK | -5.04% |
| 2016 Q2 | -23.48 Million SEK | -54.05% |
| 2016 Q1 | -15.24 Million SEK | 0.0% |
| 2015 FY | -53.34 Million SEK | -61.18% |
| 2014 FY | -33.09 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 46.564% |
| AcouSort AB (publ) | -17.08 Million SEK | -1357.727% |
| Active Biotech AB (publ) | -45.8 Million SEK | -443.91% |
| Alzinova AB (publ) | -16.48 Million SEK | -1411.596% |
| Amniotics AB (publ) | -30.87 Million SEK | -706.968% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -1841.932% |
| BioArctic AB (publ) | 229.24 Million SEK | 208.664% |
| Camurus AB (publ) | 431.44 Million SEK | 157.739% |
| Cantargia AB (publ) | -280.02 Million SEK | 11.04% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -1081.125% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -1419.157% |
| Genovis AB (publ.) | 61.5 Million SEK | 505.059% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | -119.824% |
| Mendus AB (publ) | -101.61 Million SEK | -145.142% |
| Kancera AB (publ) | -64.88 Million SEK | -283.903% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 4725.158% |
| LIDDS AB (publ) | -40.2 Million SEK | -519.587% |
| Lipum AB (publ) | -37.17 Million SEK | -570.049% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -1954.016% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 2147.095% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -1291.915% |
| NextCell Pharma AB | -41.95 Million SEK | -493.689% |
| OncoZenge AB (publ) | -15.9 Million SEK | -1466.539% |
| Saniona AB (publ) | -95.81 Million SEK | -160.005% |
| Simris Alg AB (publ) | -37.3 Million SEK | -567.768% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 19.885% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 35.825% |
| Xintela AB (publ) | -54.08 Million SEK | -360.609% |
| Ziccum AB (publ) | -21.41 Million SEK | -1063.418% |
| Isofol Medical AB (publ) | -37.07 Million SEK | -571.983% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | -38.652% |
| CombiGene AB (publ) | -35.66 Million SEK | -598.467% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | -64.051% |
| Intervacc AB (publ) | -102.85 Million SEK | -142.203% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | -0.211% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -56774.658% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -1407.662% |
| Corline Biomedical AB | -1.8 Million SEK | -13670.647% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | -40.077% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | -338.414% |
| Aptahem AB (publ) | -11.11 Million SEK | -2141.644% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | -102.417% |
| Fluicell AB (publ) | -26.55 Million SEK | -838.13% |
| Biovica International AB (publ) | -124.82 Million SEK | -99.571% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -489.989% |
| Abliva AB (publ) | -95.5 Million SEK | -160.825% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 23.796% |
| 2cureX AB (publ) | -32.51 Million SEK | -666.071% |
| I-Tech AB | 20.2 Million SEK | 1333.04% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 70.049% |
| Cyxone AB (publ) | -22.98 Million SEK | -983.61% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | -172.547% |
| Biosergen AB | -27.03 Million SEK | -821.371% |
| Nanologica AB (publ) | -75.15 Million SEK | -231.454% |
| SynAct Pharma AB | -215.81 Million SEK | -15.431% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | -465.467% |
| BioInvent International AB (publ) | -330.3 Million SEK | 24.581% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -949.463% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -2408.668% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | -127.94% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -2033.165% |